Bicara Therapeutics Q3 net loss rises to $71.2 million from $36.3 million
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Key points
- Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
- Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
- Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
- Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
The filing
Written by AI on Nov 9, 2026, 8:10 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.